Neurocrine (NB3) Stock Forecast, Price Targets and Analysts Predictions

NB3 Analyst Ratings

Strong Buy

23 Buy

3 Hold

0 Sell

Based on 26 analysts giving stock ratings to

Neurocrine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NB3 Stock 12 Month Forecast

Average Price Target

―

Based on 26 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is CHF170.98 with a high forecast of CHF202.15 and a low forecast of CHF133.96. The average price target represents a ― change from the last price of ―.

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

Highest Price TargetCHF202.15

Average Price TargetCHF170.98

Lowest Price TargetCHF133.96

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Cory Kasimov

Evercore ISI

CHF170.49→CHF174.55

Buy

―

Reiterated

08/17/26

Analysts Offer Insights on Healthcare Companies: OmniAb (NASDAQ: OABI), Neurocrine (NASDAQ: NBIX) and Evaxion Biotech (NASDAQ: EVAX)

Evan Seigerman

BMO Capital

CHF154.25

Hold

―

Reiterated

08/17/26

Neurocrine (NBIX) Gets a Hold from BMO Capital

Sean Laaman

Morgan Stanley

CHF159.12→CHF147.76

Hold

―

Assigned

08/13/26

Morgan Stanley Remains a Hold on Neurocrine (NBIX)

David Hoang

Deutsche Bank

CHF154.25→CHF133.96

Hold

―

Assigned

08/13/26

Deutsche Bank Sticks to Its Hold Rating for Neurocrine (NBIX)

Jeffrey Walch

Bernstein

CHF179.42→CHF176.98

Buy

―

Reiterated

08/12/26

Analysts' Top Healthcare Picks: Neurocrine (NBIX), Aquestive Therapeutics (AQST)

Anupam Rama

J.P. Morgan

CHF150.19→CHF176.17

Buy

―

Reiterated

08/06/26

J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)

Laura Chico

Wedbush

CHF150.19→CHF157.5

Buy

―

Reiterated

08/03/26

Neurocrine price target raised to $194 from $185 at WedbushNeurocrine price target raised to $194 from $185 at Wedbush

Danielle Brill

Truist Financial

CHF172.92

Buy

―

Reiterated

08/03/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Neurocrine (NASDAQ: NBIX) and Genmab (NASDAQ: GMAB)

Yigal Nochomovitz

Citi

CHF199.72→CHF202.15

Buy

―

Reiterated

08/03/26

Neurocrine price target raised to $249 from $246 at CitiNeurocrine price target raised to $249 from $246 at Citi

Sumant Kulkarni

Canaccord Genuity

CHF162.37→CHF170.49

Buy

―

Reiterated

08/03/26

Neurocrine (NBIX) Receives a Buy from Canaccord Genuity

Myles Minter

William Blair

―

Buy

―

Reiterated

07/31/26

Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating

Ami Fadia

Needham

CHF162.37→CHF165.62

Buy

―

Assigned

07/31/26

Neurocrine Biosciences: Strong Q2 Beat, Upgraded Outlook, and Price Target Raised to $204 Support Buy Rating

Yatin Suneja

Guggenheim

CHF162.37→CHF180.23

Buy

―

Reiterated

07/31/26

Neurocrine price target raised to $222 from $200 at GuggenheimNeurocrine price target raised to $222 from $200 at Guggenheim

Andrew Fein

H.C. Wainwright

CHF174.55

Buy

―

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)

Jay Olson

Oppenheimer

CHF186.73

Buy

―

Reiterated

07/31/26

Oppenheimer Sticks to Their Buy Rating for Neurocrine (NBIX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Cory Kasimov

Evercore ISI

CHF170.49→CHF174.55

Buy

―

Reiterated

08/17/26

Analysts Offer Insights on Healthcare Companies: OmniAb (NASDAQ: OABI), Neurocrine (NASDAQ: NBIX) and Evaxion Biotech (NASDAQ: EVAX)

Evan Seigerman

BMO Capital

CHF154.25

Hold

―

Reiterated

08/17/26

Neurocrine (NBIX) Gets a Hold from BMO Capital

Sean Laaman

Morgan Stanley

CHF159.12→CHF147.76

Hold

―

Assigned

08/13/26

Morgan Stanley Remains a Hold on Neurocrine (NBIX)

David Hoang

Deutsche Bank

CHF154.25→CHF133.96

Hold

―

Assigned

08/13/26

Deutsche Bank Sticks to Its Hold Rating for Neurocrine (NBIX)

Jeffrey Walch

Bernstein

CHF179.42→CHF176.98

Buy

―

Reiterated

08/12/26

Analysts' Top Healthcare Picks: Neurocrine (NBIX), Aquestive Therapeutics (AQST)

Anupam Rama

J.P. Morgan

CHF150.19→CHF176.17

Buy

―

Reiterated

08/06/26

J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)

Laura Chico

Wedbush

CHF150.19→CHF157.5

Buy

―

Reiterated

08/03/26

Neurocrine price target raised to $194 from $185 at WedbushNeurocrine price target raised to $194 from $185 at Wedbush

Danielle Brill

Truist Financial

CHF172.92

Buy

―

Reiterated

08/03/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Neurocrine (NASDAQ: NBIX) and Genmab (NASDAQ: GMAB)

Yigal Nochomovitz

Citi

CHF199.72→CHF202.15

Buy

―

Reiterated

08/03/26

Neurocrine price target raised to $249 from $246 at CitiNeurocrine price target raised to $249 from $246 at Citi

Sumant Kulkarni

Canaccord Genuity

CHF162.37→CHF170.49

Buy

―

Reiterated

08/03/26

Neurocrine (NBIX) Receives a Buy from Canaccord Genuity

Myles Minter

William Blair

―

Buy

―

Reiterated

07/31/26

Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating

Ami Fadia

Needham

CHF162.37→CHF165.62

Buy

―

Assigned

07/31/26

Neurocrine Biosciences: Strong Q2 Beat, Upgraded Outlook, and Price Target Raised to $204 Support Buy Rating

Yatin Suneja

Guggenheim

CHF162.37→CHF180.23

Buy

―

Reiterated

07/31/26

Neurocrine price target raised to $222 from $200 at GuggenheimNeurocrine price target raised to $222 from $200 at Guggenheim

Andrew Fein

H.C. Wainwright

CHF174.55

Buy

―

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)

Jay Olson

Oppenheimer

CHF186.73

Buy

―

Reiterated

07/31/26

Oppenheimer Sticks to Their Buy Rating for Neurocrine (NBIX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

3 Months

Jay OlsonOppenheimer

Success Rate

17/26 ratings generated profit

Average Return

+3.54%

Copying Jay Olson's trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +3.54% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

14/19 ratings generated profit

Average Return

+6.32%

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +6.32% per trade.

2 Years

Tazeen AhmadBank of America Securities

Success Rate

16/19 ratings generated profit

Average Return

+14.34%

Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 84.21% of your transactions generating a profit, with an average return of +14.34% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NB3 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

10

7

8

4

1

Buy

27

26

30

44

36

Hold

6

8

Sell

0

Strong Sell

0

total

43

41

46

56

45

In the current month, NB3 has received 37 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. NB3 average Analyst price target in the past 3 months is 170.98.

Each month's total comprises the sum of three months' worth of ratings.

NB3 Financial Forecast

NB3 Earnings Forecast

Next quarter’s earnings estimate for NB3 is CHF1.55 with a range of CHF1.08 to CHF1.94. The previous quarter’s EPS was CHF1.13. NB3 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NB3 has Performed in-line its overall industry.

NB3 Sales Forecast

Next quarter’s sales forecast for NB3 is CHF848.50M with a range of CHF817.90M to CHF894.05M. The previous quarter’s sales results were CHF780.16M. NB3 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NB3 has Performed in-line its overall industry.

NB3 Stock Forecast FAQ

What is CH:NB3’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurocrine’s 12-month average price target is 170.98.

What is CH:NB3’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for CH:NB3, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Neurocrine a Buy, Sell or Hold?

Neurocrine has a consensus rating of Strong Buy, which is based on 23 buy ratings, 3 hold ratings and 0 sell ratings.

What is Neurocrine’s share price target?

The average share price target for Neurocrine is 170.98. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF202.15 ,and the lowest forecast is CHF133.96. The average share price target represents N/A Increase from the current price of N/A.

What do analysts say about Neurocrine?

Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 26 Wall Streets Analysts.

How can I buy shares of Neurocrine?

To buy shares of CH:NB3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Neurocrine (NB3) Stock Forecast & Price Target

NB3 Analyst Ratings

NB3 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurocrine

NB3 Analyst Recommendation Trends

NB3 Financial Forecast

NB3 Earnings Forecast

NB3 Sales Forecast

NB3 Stock Forecast FAQ

Detailed List of Analyst Forecasts